Arbutus Biopharma
ABUS
167 hedge funds and large institutions have $625M invested in Arbutus Biopharma in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 48 increasing their positions, 48 reducing their positions, and 31 closing their positions.
7.65% more ownership
Funds ownership: 63.45% → 71.1% (+7.7%)
7% more capital invested
Capital invested by funds: $587M → $625M (+$38.5M)
0% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 48
6% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 31
3% less funds holding
Funds holding: 172 → 167 (-5)
20% less call options, than puts
Call options by funds: $2.67M | Put options by funds: $3.34M
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSC
Two Seas Capital
Rye,
New York
|
+$26.1M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$22.1M |
| 3 |
Barclays
London,
United Kingdom
|
+$17.3M |
| 4 |
Legal & General Group
London,
United Kingdom
|
+$9.96M |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$8.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$9.98M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.32M |
| 3 |
SC
Stempoint Capital
New York
|
-$4.75M |
| 4 |
Morgan Stanley
New York
|
-$3.55M |
| 5 |
SCM
Saba Capital Management
New York
|
-$1.67M |
ABUS Hedge Fund Activity: Q1 2026 in Review
167 of the 8,190 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2026, worth a combined $625M — up 6.6% from $587M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of ABUS and 29 opened new positions — a net loss of 2 holders — while 48 trimmed existing stakes and 48 added.
The largest buyer was Two Seas Capital, adding an estimated $26.1M. The largest seller was ADAR1 Capital Management, cutting an estimated $9.98M.
- 167 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2026, down from 172 in Q4 2025.
- Funds reported $625M of Arbutus Biopharma stock for Q1 2026, up 6.6% quarter-over-quarter.
- 29 funds opened new Arbutus Biopharma positions in Q1 2026 and 31 closed out, a net change of -2 holders.
- The largest Arbutus Biopharma buyer in Q1 2026 was Two Seas Capital, an estimated $26.1M added.
- The largest Arbutus Biopharma seller in Q1 2026 was ADAR1 Capital Management, an estimated $9.98M sold.
Based on aggregated 13F filings for Q1 2026.